20/20 GeneSystems

20/20 GeneSystems

Growth Stage

Pioneering the Multi-Cancer Early Detection (MCED) blood testing market

Pioneering the Multi-Cancer Early Detection (MCED) blood testing market

Overview

Raised to Date: Raised: $116,019

Total Commitments ($USD)

Platform

Wefunder

Start Date

05/05/2024

Close Date

09/04/2024

Min. Goal
$50,000
Max. Goal
$5,000,000
Min. Investment

$500

Security Type

Equity - Preferred

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$5.34

Pre-Money Valuation

$69,859,000

Rolling Commitments ($USD)

Status

Active

Reporting Date

05/25/2024

Days Remaining

101

% of Min. Goal

232%

% of Max. Goal

2%

Likelihood of Max
unlikely
Avg. Daily Raise

$5,801

# of Investors

70

Momentum
cold.svg
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2000

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B/B2C

Margin

Medium

Capital Intensity

Low

Location

Rockville, Maryland

Business Type

Growth

20/20 GeneSystems, with a valuation of $69.86 million, is raising funds on Wefunder. It is a diagnostics company with a successful track record in cancer detection with its AI-powered multi-cancer blood test, OneTest. OneTest is a multi-cancer early detection test that measures antigens that tend to rise early in tumor development and enable early detection of cancer. The business has multiple issued or allowed patents in the US and East Asia and has partnered with a leading cancer center and a major supermarket chain for in-pharmacy testing. Jonathan Cohen founded 20/20 GeneSystems in May 2000. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5 million. The campaign proceeds will be used for sales, marketing, R&D, and operational and administrative staffing to enable growth.

Summary Profit and Loss Statement

FY 2023 FY 2022

Revenue

$1,424,304

$11,059,145

COGS

$1,315,166

$5,937,398

Tax

$0

$0

 

 

Net Income

$-6,391,309

$2,186,875

Summary Balance Sheet

FY 2023 FY 2022

Cash

$4,089,461

$8,807,575

Accounts Receivable

$68,834

$764,924

Total Assets

$6,367,828

$12,215,021

Short-Term Debt

$1,011,623

$1,630,171

Long-Term Debt

$1,068,713

$1,210,584

Total Liabilities

$2,080,336

$2,840,755

Financials as of: 05/05/2024
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
20/20 GeneSystems 09/03/2024 Wefunder $69,859,000 $116,019 Equity - Preferred Active RegCF
20/20 GeneSystems 12/20/2022 StartEngine $58,400,000 $232,704 Convertible Note Funded RegCF
20/20 GeneSystems 06/26/2021 StartEngine $38,500,000 $2,903,017 Equity - Preferred Funded RegA+
20/20 GeneSystems 10/31/2020 SeedInvest $38,500,000 $3,792,229 Equity - Preferred Funded RegA+
20/20 GeneSystems 12/13/2017 Microventures $23,000,000 $1,064,807 Equity - Preferred Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
20/20 GeneSystems on Wefunder 2024
Platform: Wefunder
Security Type: Equity - Preferred
Valuation: $69,859,000
Price per Share: $5.34

Follow company

Follow 20/20 GeneSystems on Wefunder 2024

Buy 20/20 GeneSystems's Deal Report

20/20 GeneSystems Deal Report

Get KingsCrowd’s comprehensive report on 20/20 GeneSystems including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether 20/20 GeneSystems is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the 20/20 GeneSystems deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge